摘要
目的 探讨瑞巴派特联合雷贝拉唑对慢性糜烂性胃炎(CEG)患者胃黏膜炎症反应的影响。方法 选取2021年1月至12月我院收治的CEG患者70例。随机分为对照组和观察组各35例。对照组采用雷贝拉唑治疗,观察组在对照组基础上加用瑞巴派特。比较两组治疗效果、症状评分、胃黏膜炎症反应及药物安全性。结果 观察组治疗总有效率为94.29%,高于对照组的71.43%,差异有统计学意义(P<0.05);两组治疗前症状评分、胃黏膜炎症反应比较,差异无统计学意义(P>0.05);治疗后,观察组症状评分各维度均低于对照组,PGE2水平高于对照组,MDA水平低于对照组,差异有统计学意义(P<0.05)。两组均未发生明显不良反应。结论 采用瑞巴派特联合雷贝拉唑治疗CEG,临床疗效显著,利于减轻患者症状,改善胃黏膜炎症反应,且安全性较高,值得推广应用。
Objectives To investigate the effect of Rebamipide combined with Rabeprazole on gastric mucosal inflammation in patients with chronic erosive gastritis(CEG).Methods A total of 70 patients with CEG admitted to our hospital from January 2021 to December 2021 were selected and randomly divided into two groups,with 35 cases in each group.The control group was treated with Rabeprazole,on which basis the observation group was treated with Rebamipide.The therapeutic effect,symptom score,gastric mucosal inflammation and drug safety were compared between the two groups.Results The total effective rate in the observation group was 94.29%,which was significantly higher than the 71.43%in the control group.There was no significant difference in symptom score and gastric mucosa inflammation between the two groups before treatment(P>0.05).After treatment,the symptom scores of the observation group were significantly lower than those of the control group,the PGE2 level was significantly higher than that in the control group,and the MDA level was significantly lower than that of the control group(P<0.05).No obvious adverse reactions occurred in both groups.Conclusions Rebamipide combined with Rabeprazole has significant clinical effects in the treatment of CEG,which alleviates the symptoms,improves the inflammatory reaction of gastric mucosa,and has high a safety,and is thus worthy of popularization and application.
作者
李平学
邓瑛
LI Pingxue;DENG Ying(Yongfeng People’s Hospital,Ji’an 331500 Jiangxi,China)
出处
《现代诊断与治疗》
CAS
2023年第5期654-656,共3页
Modern Diagnosis and Treatment
